Evidence Snapshot

Muscarinic acetylcholine receptor

CHEMBL2094109 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:04:34Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:04 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2094109

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscarinic acetylcholine receptor as ChEMBL target CHEMBL2094109, mapped to UniProt P20309. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Muscarinic acetylcholine receptor

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2094109

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P20309

Muscarinic acetylcholine receptor M3

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Muscarinic acetylcholine receptor matters

As of 2026-09-13

Muscarinic acetylcholine receptor is reviewed as Muscarinic acetylcholine receptor M3 (UniProt P20309); Muscarinic acetylcholine receptor shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 593 compounds, and 129 assays, with lead potency reaching pChEMBL 10.9.

Protein context

Muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M3 Sequence length is 590 aa.

Review this target as Muscarinic acetylcholine receptor, mapped to UniProt P20309. ChEMBL maps the protein component as Muscarinic acetylcholine receptor M3. Sequence length is 590 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P20309 Protein

Disease context

chronic obstructive pulmonary disease

Muscarinic acetylcholine receptor shows approved-linked disease relevance led by chronic obstructive pulmonary disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DAROTROPIUM BROMIDE, GLYCOPYRRONIUM TOSYLATE.

Start review with chronic obstructive pulmonary disease because it currently carries approved-linked support. Linked drugs include DAROTROPIUM BROMIDE, GLYCOPYRRONIUM TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 2 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 593 compounds, and 129 assays for this target. The dominant activity type is KI. CHEMBL318812 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL318812 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine

11 approved pChEMBL 10.9

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P20309, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic obstructive pulmonary disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

593

Total Compounds

129

Total Assays

Approved Drugs

IC50: 118.0, KI: 386.0, EC50: 58.0, KD: 149.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL318812	10.9	Kd	—
No preferred name CHEMBL320611	10.5	Kd	—
No preferred name CHEMBL12980	10.3	Ki	—
No preferred name CHEMBL320611	10.3	Ki	—
No preferred name CHEMBL287868	9.6	Ki	—